InjectionMRP Under Process
Official PMBI MRP is being updated for catalog code 2769.
Locate Jan Aushadhi KendraClinical Overview
Vincristine Sulfate Injection (1mg) is a natural vinca alkaloid antineoplastic on the WHO Model List of Essential Medicines. It binds specifically to tubulin dimers, preventing their polymerization into microtubules and causing mitotic spindle dissolution, arresting proliferating cells in metaphase (M phase). Indicated as an essential backbone component for acute lymphoblastic leukemia (ALL), Hodgkin and non-Hodgkin lymphomas, neuroblastoma, rhabdomyosarcoma, and Wilms tumor.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
CRITICAL ADMINISTRATION SAFETY MANDATE: Administer INTRAVENOUSLY ONLY. Dispense in an intravenous infusion mini-bag (50 mL 0.9% NaCl) and infuse over 5 to 10 minutes. NEVER dispense or administer vincristine in a syringe to prevent accidental intrathecal injection. Standard maximum single dose is capped at 2.0 mg to prevent catastrophic neurotoxicity.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dose-limiting peripheral neurotoxicity (loss of deep tendon reflexes, finger/toe numbness, foot drop, wrist drop), severe constipation and paralytic ileus (autonomic neuropathy), alopecia. Minimal bone marrow suppression. Rare/Severe: FATAL neurotoxicity if given intrathecally, vocal cord paralysis, SIADH (hyponatremia), and severe vesicant extravasation ulceration.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
BLACK BOX FATAL WARNING: FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN BY OTHER ROUTES. Intrathecal administration causes ascending encephalomyelopathy and 100% fatal destruction of the central nervous system. Cap single doses at 2 mg. Autonomic neuropathy causes severe paralytic ileus; institute prophylactic bowel regimens. Vesicant agent.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.